# OnCo record medicare-negotiation-2027-cancer-drugs (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/medicare-negotiation-2027-cancer-drugs/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "medicare-negotiation-2027-cancer-drugs" ;
  schema:name "Medicare negotiated prices from 2027: enzalutamide, pomalidomide, palbociclib and acalabrutinib"@en ;
  schema:alternateName "IPAY 2027"@en, "second cycle of Medicare drug price negotiation"@en, "Xtandi maximum fair price"@en, "Pomalyst maximum fair price"@en, "Ibrance maximum fair price"@en, "Calquence maximum fair price"@en ;
  schema:description "Of the fifteen drugs whose Medicare-negotiated prices start on 1 January 2027, four are cancer medicines: Xtandi (enzalutamide), Pomalyst (pomalidomide), Ibrance (palbociclib) and Calquence (acalabrutinib)."@en ;
  schema:url <https://onco.cc/terms/medicare-negotiation-2027-cancer-drugs/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.cms.gov/files/zip/cms-negotiation-program-selected-drug-list-maximum-fair-price-data-file-20261102.zip>, <https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program> ;
  onco:tag "law", "us" ;
  onco:related <https://onco.cc/terms/medicare-negotiation-2026-cancer-drug/>, <https://onco.cc/terms/medicare-negotiation-2028-cancer-drugs/> ;
  onco:drugs <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/pomalidomide/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/acalabrutinib/> ;
  onco:terms <https://onco.cc/terms/inflation-reduction-act/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-drug-pricing/> .